SCHEMBL5358671

SCHEMBL5358671

Cc1cc(C=C2C(=O)Nc3ccc(Br)c(C)c32)oc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 7/20 0.39
ALDH1A1 P00352 3/20 0.38
MAPT P10636 2/20 0.38
RPS6KA3 P51812 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
LMNA P02545 2/20 0.37
DYRK1A Q13627 1/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
ALOX12 P18054 1/20 0.37
PDPK1 O15530 1/20 0.36
KDR P35968 1/20 0.36
PTPN1 P18031 2/20 0.35
RECQL P46063 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PDGFRB P09619 2/20 0.34
ERBB2 P04626 1/20 0.34
RAF1 P04049 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367431 0.82 RET (0.55) RETALDH1A1MAPTRPS6KA3MEN1
SCHEMBL5364403 0.82 KMT2A (0.56) RETALDH1A1MAPTMEN1KMT2A
SCHEMBL5372795 0.81 PIM1 (0.45) RETALDH1A1MAPTRPS6KA3MEN1
SCHEMBL7131028 0.81 ALDH1A1 (0.33) RETALDH1A1MAPTMEN1KMT2A
SCHEMBL5368693 0.81 MAPT (0.39) RETALDH1A1MAPTMEN1KMT2A
SCHEMBL6855418 0.79 RPS6KA3 (0.62) RETALDH1A1MAPTRPS6KA3MEN1
SCHEMBL6830072 0.79 RPS6KA3 (0.62) RETALDH1A1MAPTRPS6KA3MEN1
SCHEMBL5367226 0.78 PTPN1 (0.44) RETALDH1A1MAPTMEN1KMT2A
SCHEMBL7138230 0.77 PTPN1 (0.43) RETALDH1A1MAPTMEN1KMT2A
SCHEMBL5366590 0.76 MEN1 (0.55) RETALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK RET 283/4885ALDH1A1 2044/4885MAPT 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.